ClinicalTrials.gg
Not yet recruitingNCT07086846Updated Jul 25, 2025

Effect of Myofascial Release Versus Acupressure on Carpal Tunnel Syndrome in Postnatal Period

An interventional study of Night splint and Myofascial release technique in Carpal Tunnel Syndrome, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 25 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
25 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Carpal Tunnel Syndrome by Cairo University — 9 open to participants now, 10 under way, none of them phase 3. Carpal Tunnel Syndrome · Cairo University.

Planned enrollment
5th of 20
60 · median 55
Started
2025
with 2 others
No phase
19 of 21
9 open now
Registered
17th of 21
by date

Among the 21 studies in Carpal Tunnel Syndrome by Cairo University, this one is the 5th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, and was the 17th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

9 of the 21 studies in Carpal Tunnel Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 25 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carpal Tunnel Syndrome by Cairo University, or all of them as a file.
02

Study summary

This study will be conducted to compare the effect of myofascial release and acupressure on postnatal carpal tunnel syndrome.

Read the detailed description

Various factors, such as an increase in body mass index (BMI), hormones (relaxin), fluid redistribution, and maternal age, are involved in the etiology of pregnancy related carpal tunnel syndrome (CTS). In terms of prognosis, although it has been reported that pregnancy related CTS generally regresses completely spontaneously or with conservative treatment methods after birth, residual symptoms and neurophysiological findings that require surgical decompression up to a year after birth have also been reported.

In clinical practice guidelines, conservative treatment is recommended for mild and moderate cases, while a surgical approach is recommended for patients with severe CTS . Some clinical conditions such as hormonal alteration and edema for menopause and pregnancy due to alteration of the fluid balance in the body.

Myofascial release is considered a safe, non-invasive, and simple method for decreasing pain intensity and numbness sensation severity and for improving hand function in pregnant women with CTS.

Acupressure is the supportive therapies based on Chinese medicine. Pressure is applied to the affected areas without the use of needles. PC7 or the Daling point is especially considered when managing CTS; it was found to cause an increase of endomorpin-1, beta-endorphin, serotonin, dopamine, and enkephalin levels in the brain tissues and plasma. Acupressure was found to be more effective compared to the placebo and splints re- garding the functional status and nerve conduction studies.

03

Conditions studied

  • Carpal Tunnel Syndrome
04

Who can participate

Ages eligible
25 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postpartum women with mild to moderate carpal tunnel syndrome (CTS).
  • Their ages will range from 25 to 35 years old.
  • Their (BMI) will range from 25 to 30 Kg/m2.
  • The electrophysiological evidence of mild or moderate median nerve lesion at wrist (mild: sensory nerve conduction velocity slow on finger/wrist measurement, sensory nerve latency >3.5 ms, normal terminal motor latency; moderate: sensory potential preserved with motor slowing, distal motor latency to abductor pollicis brevis (APB) \< 6.5 ms)
  • Positive phalen's test.
  • Positive tinel's test.
  • Unilateral or bilateral carpal tunnel affection will be included.

Exclusion criteria

Exclusion Criteria:

  • History of brachial plexopathy or .
  • Radial, ulnar neuropathy, proximal median neuropathy or polyneuropathy.
  • Previous wrist surgery or injection for CTS.
  • History of trauma, fracture, deformity or inflammation in the wrist, such as rheumatoid arthritis.
  • Coagulation abnormalities, pregnancy, fever and infections.
  • Skin disease and skin cancer.
  • Spots, birthmarks or tattoos over the work points.
  • Pacemaker and implementable medical devices.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Myofascial release technique

    The participants will receive myofascial release, for 15 minutes, three times per week for 6 weeks (total of 18 sessions), in addition to night splint and home advice.

    Other: Night splint · Other: Myofascial release technique · Other: Home advice

  • Experimental
    Acupressure

    The participants will receive acupressure on pericardium 6 acupoint (PC-6 point) for 3 minutes, three times per week for 6 weeks (total of 18 sessions), in addition to night splint and home advice.

    Other: Night splint · Other: Acupressure · Other: Home advice

Interventions

  • OtherNight splint

    All participants will be treated conservatively by wrist splint in a neutral position.

  • OtherMyofascial release technique

    The participant will receive myofascial release using M2T blade. It will be applied on the carpal tunnel over and above the wrist creases on the ventral aspect of the forearm for 15 minutes, 3 sessions weekly for 6 weeks (total of 18 sessions).

  • OtherAcupressure

    It will be applied on the pericardium 6 point (PC-6) for 3 minutes, three times per week for 6 weeks (total of 18 sessions). It is located on the palm side of the wrist a couple of inches toward the body in between the two tendons (palmaris longus \& flexor carpi radialis) that run approximately down the center of the forearm.

  • OtherHome advice

    The participants will be asked to follow important advices like supporting the wrists during activity and ensuring proper posture, avoiding wrist flexion and extension, avoiding hard clutches, holding or carrying objects for a long time, catching with fingers, repetitive hand and wrist movement such as knitting or sewing, driving, activities and hobbies such as golf, tennis, table tennis.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    The visual analogue scale (VAS) will be used to assess pain intensity before and after intervention. The VAS is usually presented as a 10-cm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable."

    Time frame: 6 weeks

  2. Sensory conduction velocity

    Electromyography device (Tru Trace EMG, 2ch Head box device, manufactured by deymed Diagnostic Pvt., Ltd., Czech Republ) will be used to assess sensory conduction velocity of median nerve before and after the treatment. A pair of ring electrodes will be placed on the index finger for recording, and the sensory nerve will be stimulated antidromically. The stimulating electrodes will be placed at the wrist proximal to carpal tunnel for the distal segment stimulation and at the elbow medial to biceps tendon for the proximal segment stimulation. Conduction velocity is the speed at which the electrical signal travels along the nerve. A reduced velocity can also indicate nerve damage. Its normal range is from 44-60 ms.

    Time frame: 6 weeks

  3. Sensory distal latency

    Electromyography device (Tru Trace EMG, 2ch Head box device, manufactured by deymed Diagnostic Pvt., Ltd., Czech Republ) will be used to assess sensory distal latency of median nerve before and after the treatment. A pair of ring electrodes will be placed on the index finger for recording, and the sensory nerve will be stimulated antidromically. The stimulating electrodes will be placed at the wrist proximal to carpal tunnel for the distal segment stimulation and at the elbow medial to biceps tendon for the proximal segment stimulation. The distal motor latency is measured from the onset of the stimulating artifact to the onset of the compound muscle action potential. Its normal range is from 2.5-3.5 ms.

    Time frame: 6 weeks

  4. Median nerve amplitude

    The amplitude of the median nerve (specifically, the sensory nerve action potential, or SNAP) will be measured by electromyography (Tru Trace EMG, 2ch Head box device, manufactured by deymed Diagnostic Pvt., Ltd., Czech Republ) during nerve conduction study before and after treatment. It is measured in microvolts (µV) and reflects the number of nerve fibers conducting the electrical signal. During a nerve conduction study, a small electrical stimulus is applied to the median nerve, and the resulting electrical activity is recorded. The amplitude is then measured as the height of the waveform generated by this activity. Its normal value should be at least 6 microvolt (6 µV).

    Time frame: 6 weeks

Secondary outcomes

  1. Assessment of severity of carpal tunnel syndrome symptoms

    Boston Carpal Tunnel Questionnaire will be used before and after intervention. It comprises two scales, a symptom severity scale (SSS) and a functional status scale (FSS). The SSS evaluates symptoms with regard to severity, frequency, and time. The FSS indicates how the syndrome affects daily life. SSS involves 11 questions, addressing: pain intensity during day time and night time, time of pain during the day, numbness, weakness, tingling sensation at night, frequency of night tingling sensation, and skill. Each question offers 5 answers, from 0 points (no symptoms) to 4 points (most severe symptoms). Questions concerning FSS refer to daily activities that will be performed by most individuals and are commonly affected by CTS. The patients rate their ability to perform each activity on a scale that ranged from 1 point (no difficulty with the activity) to 5 points (cannot perform the activity at all).The overall score for the FSS is the mean of the ratings on the daily activities.

    Time frame: 6 weeks

07

Study locations

1 site
  • Amr Kamal Abd El-Aal
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Oct 2025, 2 months later.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 2 months is below that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Jul 25, 2025
StartEst.
Jul 27, 2025
Primary completionEst.
Oct 20, 2025
CompletionEst.
Oct 30, 2025
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07086846
Lead sponsor
Cairo University
Responsible party
Amr Kamal Abd El-Aal Mansour (Principal investigator, Cairo University) — Principal investigator
First posted
Jul 25, 2025
Start date
Jul 27, 2025 (estimated)
Primary completion
Oct 20, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Jul 25, 2025

Study contacts

Amr Abd El-Aal, PHD
Contact
ak9779825@gmail.com
01113697786
Amr Abbasy, Professor
Contact
abbassy2002@hotmail.com
0100446860
Afaf Botla, Professor
study director · Cairo University
Soheir El-kosery, Professor
study chair · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion